The Difference Between Wegovy, Ozempic, Mounjaro, and Zepbound (in Plain English)

If you've been researching obesity medications, you've probably come across a confusing cluster of brand names: Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, Contrave. They sound similar. Some seem to work the same way. And you might have heard that "Ozempic is just cheaper Wegovy" — which is partly true and partly misleading.

The confusion isn't your fault. The pharmaceutical landscape here is genuinely unusual: two pairs of drugs exist where each pair shares the same active ingredient, but one is approved for diabetes and the other for obesity — and insurance treats them very differently.

Here's a clear breakdown of what each medication is, how it works, and why these distinctions matter for coverage.

The Big Picture: Two Drug Classes, Four Brand Names

The medications most people are asking about fall into two categories based on how they work:

GLP-1 receptor agonists These drugs mimic a hormone called GLP-1 (glucagon-like peptide-1), which your body releases after eating. GLP-1 tells your brain you're full, slows digestion, and helps regulate blood sugar. In this category:

• Ozempic (semaglutide, Novo Nordisk) — FDA-approved for type 2 diabetes
• Wegovy (semaglutide, Novo Nordisk) — FDA-approved for chronic weight management

GLP-1/GIP dual agonists These drugs mimic two hormones — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Adding GIP appears to produce more significant weight loss than GLP-1 alone. In this category:

• Mounjaro (tirzepatide, Eli Lilly) — FDA-approved for type 2 diabetes
• Zepbound (tirzepatide, Eli Lilly) — FDA-approved for chronic weight management (and sleep apnea)

So to summarize: Ozempic and Wegovy are the same drug. Mounjaro and Zepbound are the same drug. The difference within each pair is the FDA-approved use — and that distinction has enormous consequences for insurance coverage.

Why the FDA Approval Matters So Much

Insurance companies don't just pay for any medication a doctor prescribes. They pay for medications that are used for covered indications — meaning the diagnosis must match what the drug is approved for.

Here's where it gets complicated:

• If you have type 2 diabetes, your insurance is much more likely to cover Ozempic or Mounjaro, because those are FDA-approved diabetes drugs. Many plans cover diabetes medications broadly.
• If you have obesity without diabetes, you're being prescribed Wegovy or Zepbound — drugs with an obesity indication. And many insurance plans either don't cover obesity drugs at all, or cover them with much stricter requirements.

This is why some people find that "Ozempic" is covered but "Wegovy" isn't — even though the active ingredient is the same. Insurers aren't paying for the molecule; they're paying for the indication.

It also means that prescribing Ozempic "off-label" for weight loss in someone who doesn't have diabetes is something insurers may deny. (Off-label means using a drug for a purpose not listed in its FDA approval.) Whether or not a doctor prescribes it that way, the claim goes through with a diagnosis code — and if that code doesn't match the drug's approved use, coverage may be denied.

Saxenda: The Older GLP-1

You may also encounter two older obesity medications that are still in use:

Saxenda (liraglutide, Novo Nordisk) Saxenda is a GLP-1 receptor agonist — the same mechanism as semaglutide — but it's an older formulation that requires daily injections rather than weekly. It's FDA-approved for chronic weight management. Because it's been on the market longer, it's sometimes on insurance formularies that don't yet cover the newer medications. It produces meaningful weight loss, though generally somewhat less than the newer weekly injectables. Victoza is the same drug (liraglutide) approved for diabetes.

How This Affects Insurance Coverage

Understanding which drug is which helps you interpret your insurance situation:

If your plan covers diabetes drugs but not obesity drugs: You may find Ozempic or Mounjaro covered if you have a diabetes diagnosis, but Wegovy or Zepbound excluded because your primary diagnosis is obesity. This is a real and frustrating disparity that patient advocates have been pushing to change.

If your plan's formulary lists one but not the other: Plans sometimes cover Wegovy but not Zepbound, or vice versa. Look up both in your formulary if your doctor thinks either could work for you.

If step therapy requires an older medication first: Your plan might require that you try Saxenda before Wegovy, or a non-GLP-1 antiobesity medication (Contrave or Qsymia) before Zepbound. Understanding what each of those drugs is helps you have a more informed conversation with your doctor about whether that path makes sense for you.

Medicare and the coverage gap: Medicare began covering some GLP-1s for cardiovascular risk reduction following regulatory changes, but coverage specifically for obesity remains limited under Medicare. If you're on Medicare, the distinction between diabetes and obesity indications is particularly important. We cover this in detail in Commercial Insurance vs. Medicare vs. Medicaid.

A Quick Reference Chart

| Brand Name | Active Ingredient | Maker | FDA Approval | Primary Coverage Context | |---|---|---|---|---| | Ozempic | Semaglutide | Novo Nordisk | Type 2 diabetes | Diabetes coverage | | Wegovy | Semaglutide | Novo Nordisk | Obesity / weight management | Obesity coverage | | Mounjaro | Tirzepatide | Eli Lilly | Type 2 diabetes | Diabetes coverage | | Zepbound | Tirzepatide | Eli Lilly | Obesity / weight management (+ sleep apnea) | Obesity coverage | | Saxenda | Liraglutide | Novo Nordisk | Obesity / weight management | Obesity coverage | | Victoza | Liraglutide | Novo Nordisk | Type 2 diabetes | Diabetes coverage |

The Bottom Line

The brand name on your prescription matters for insurance purposes — not just because of cost differences, but because of fundamentally different coverage policies. Wegovy and Ozempic are the same molecule; Zepbound and Mounjaro are the same molecule. But their FDA indications create different insurance pathways.

The good news is that your doctor knows these distinctions well and can help you navigate which medication makes sense for your situation and which path gives you the best chance of coverage. If one route is blocked, there may be another way forward — but those decisions should be made clinically, not just strategically.